Get the Stockscreener App
5.60
0.18%
-0.01
After Hours:
5.55
-0.05
-0.89%
Rxsight Inc stock is traded at $5.60, with a volume of 1.07M.
It is down -0.18% in the last 24 hours and up +12.00% over the past month.
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.
See More
Previous Close:
$5.61
Open:
$5.52
24h Volume:
1.07M
Relative Volume:
1.12
Market Cap:
$231.82M
Revenue:
$134.48M
Net Income/Loss:
$-38.94M
P/E Ratio:
-5.8737
EPS:
-0.9534
Net Cash Flow:
$-19.34M
1W Performance:
+9.80%
1M Performance:
+12.00%
6M Performance:
-43.94%
1Y Performance:
-57.09%
1-Day Range:
$5.43
$5.76
1-Week Range:
$4.725
$5.76
52-Week Range:
$4.48
$13.36
Rxsight Inc Stock (RXST) Company Profile
Name
Rxsight Inc
Sector
Industry
Phone
949-521-7822
Address
100 COLUMBIA STREET, ALISO VIEJO
Compare RXST vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RXST
Rxsight Inc
|
5.60 | 199.53M | 134.48M | -38.94M | -19.34M | -0.9534 |
ABT
Abbott Laboratories
|
95.63 | 158.05B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
324.73 | 120.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.06 | 100.14B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.60 | 63.44B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
95.18 | 52.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Initiated | William Blair | Mkt Perform |
| Jul-15-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-10-25 | Downgrade | Jefferies | Buy → Hold |
| Jul-09-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-09-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-09-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-19-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-15-25 | Initiated | Piper Sandler | Neutral |
| Apr-09-25 | Downgrade | UBS | Buy → Neutral |
| Apr-04-25 | Downgrade | JP Morgan | Overweight → Underweight |
| Apr-03-25 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-20-24 | Downgrade | Stifel | Buy → Hold |
| Dec-11-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-06-24 | Initiated | UBS | Buy |
| Oct-29-24 | Initiated | Jefferies | Buy |
| Aug-20-24 | Reiterated | Needham | Buy |
| Aug-06-24 | Reiterated | Needham | Buy |
| May-07-24 | Reiterated | BTIG Research | Buy |
| Dec-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-12-23 | Initiated | Stifel | Buy |
| Dec-04-23 | Initiated | Morgan Stanley | Overweight |
| Apr-13-23 | Initiated | Oppenheimer | Outperform |
| Dec-12-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-08-22 | Initiated | Needham | Buy |
View All
Rxsight Inc Stock (RXST) Latest News
Bronstein, Gewirtz & Grossman, LLC Encourages RxSight, Inc. (RXST - The National Law Review
RxSight, Inc.(NasdaqGM: RXST) dropped from Russell 2500 Growth Benchmark - marketscreener.com
RxSight, Inc.(NasdaqGM: RXST) added to Russell Microcap Value Benchmark Index - marketscreener.com
RxSight, Inc.(NasdaqGM: RXST) added to Russell 2000 Value Benchmark - marketscreener.com
RxSight, Inc.(NasdaqGM: RXST) dropped from Russell 2000 Growth Benchmark - marketscreener.com
RxSight, Inc.(NasdaqGM: RXST) dropped from Russell 3000E Growth Benchmark - marketscreener.com
RxSight, Inc.(NasdaqGM: RXST) added to Russell Microcap Index - marketscreener.com
Class Action Alert: Levi & Korsinsky Reminds RxSight, Inc. (RXST) Investors of September 22, 2025 Deadline - The National Law Review
Liquidity Mapping Around (RXST) Price Events - Stock Traders Daily
RXST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
RXST Stockholders Have Opportunity to Lead RxSight, Inc. Class Ac - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating RxSight, Inc. (RXST) And Encourages Investors to Connect - The National Law Review
Lost Money on RxSight, Inc. (RXST)? Contact Levi & Korsinsky Before September 22, 2025 to Join Class Action - The National Law Review
RxSight, Inc. (RXST) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review
RXST SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
RXST Forecast — Price Target — Prediction for 2027 - TradingView
RxSight, Inc. Actuals & Estimates (NASDAQ:RXST) - TradingView
RxSight, Inc. Actuals & Estimates (BOATS:RXST) - TradingView
Rxsight Inc (RXST) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
RXST SEC FilingsRxsight, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Rxsight Inc (RXST) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
RxSight (RXST) director receives 37,037 restricted stock units in equity grant - Stock Titan
RxSight (RXST) director awarded 37,037 RSUs in equity compensation grant - Stock Titan
RxSight (RXST) director Shweta Maniar receives 37,037 RSU award - Stock Titan
Tamara Fountain at RxSight (RXST) receives 37,037-share RSU award - Stock Titan
RxSight (RXST) director William J. Link granted 37,037-share stock award - Stock Titan
RxSight (RXST) director Corley Jesse Anderson granted 37,037 RSUs - Stock Titan
RxSight (RXST) director granted 30,864 RSUs vesting by next meeting - Stock Titan
RxSight (RXST) director receives 37,037 RSUs vesting by next stockholder meeting - Stock Titan
RxSight (RXST) director receives 37,037 RSUs, now directly holds 85,183 shares - Stock Titan
Rxsight Inc (RXST) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rxsight Inc (RXST) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
RxSight Stockholders Back Leadership at 2026 Annual Meeting - The Globe and Mail
Rxsight Inc (RXST) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Rxsight Inc (RXST) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Rxsight Inc (RXST) Institutional Confidence - TradingKey
Rxsight Inc (RXST) Valuation: PE, PB & Fair Value Analysis - TradingKey
Rxsight Inc (RXST) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
RxSight (RXST) investors re-elect board, approve pay and ratify Ernst & Young - Stock Titan
RxSight Inc Stock (US78419L1008): Valuation Focus After Strong Run In Eye Technology - AD HOC NEWS
RxSight, Inc. Hits 52-Week Low of $4.58 Amidst 92.2% Decline - MarketsMojo
RxSight, Inc. Stock Plummets to New 52-Week Low of $4.49 - MarketsMojo
RxSight, Inc. (RXST) Reports Q3 Loss, Tops Revenue Estimates - MSN
RxSight Inc. (RXST) Falters Near Support: Testing Key Levels After 1.96% DeclineDark Pool Sentiment - newsline.com
Understanding Momentum Shifts in (RXST) - Stock Traders Daily
RxSight, Inc. Hits 52-Week Low at $5.31 Amid Ongoing Struggles - MarketsMojo
RxSight, Inc. Hits 52-Week Low at USD 4.93 Amidst Ongoing Struggles - MarketsMojo
RxSight Inc. (RXST) Slides 3% as Stock Struggles Below Key Resistance at $5.03Put Wall - newsline.com
RxSight Inc. (RXST) Q1 2026 Earnings: EPS Miss Weighs on Shares Amid Operating ChallengesProfitability Analysis - newsline.com
RXST Technical Analysis & Stock Price Forecast - Intellectia AI
RxSight Inc stock (US78419L1008): Nasdaq-listed eye-care specialist in focus after recent price weak - AD HOC NEWS
Rxsight Inc Stock (RXST) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rxsight Inc Stock (RXST) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Goldshleger Ilya | See remarks |
Sep 25 '25 |
Option Exercise |
4.27 |
23,445 |
99,998 |
65,691 |
2.62%
2.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):